Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
CJC-1295 + ipamorelin are injected together once or twice a day
Clinical trial data highlighted at the 2026 American Diabetes Association Scientific Sessions shows that Foundayo is remarkably effective for midlife weight management
Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
Who can use GLP-1 for Weight Loss
In studies using high doses of semaglutide 2.4 mg over 68 weeks, people lose on average 15-20% of their body weight
Walker RF
